Cargando…

Anti-HER2 imaging agents for breast cancer imaging

Detalles Bibliográficos
Autores principales:	Tolner, B, Vigor, K, Mather, S, Robinson, M, Adams, G, Plueckthun, A, Chester, K
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875604/ http://dx.doi.org/10.1186/bcr2539

Ejemplares similares

Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging
por: Goldstein, Robert, et al.
Publicado: (2014)

Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer
por: Da Pieve, C, et al.
Publicado: (2006)

Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer
por: Da Pieve, C, et al.
Publicado: (2008)

Fucoidan extract enhances the anti-cancer activity of chemotherapeutic agents in breast cancer cells
por: Shirahata, Sanetaka, et al.
Publicado: (2013)

Opticin: a potent anti-angiogenic/antiproliferative agent for breast cancer therapy
por: Sneddon, SF, et al.
Publicado: (2010)

Peripheral blood mononuclear cells of breast cancer patients can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells
por: Payne, Kyle K, et al.
Publicado: (2013)

HER2 upregulates fatty acid synthase and acetyl-CoA carboxylase at a translational level in breast cancer cells
por: Yoon, S, et al.
Publicado: (2005)

Contrast-enhanced MR imaging of pulmonary arteries: new imaging strategies using different contrast agents
por: Makowski, Marcus R, et al.
Publicado: (2009)

Imaging features of male breast cancer: a pictorial review
por: Lloyd, CR, et al.
Publicado: (2008)

Use of ultrasound elasticity imaging to monitor the response of a primary breast cancer to neoadjuvant chemotherapy in one patient in a pilot study
por: English, RE, et al.
Publicado: (2011)

Imaging the breast following neoadjuvant chemotherapy: does improvement of imaging findings in the axilla predict pathological response in the breast?
por: Williams, A, et al.
Publicado: (2012)

Does breast magnetic resonance imaging measurement correlate with pathology in assessment of primary breast cancer?
por: Khan, AN, et al.
Publicado: (2009)

Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53 mutant Her2 and triple negative breast cancer
por: Sainsbury, R, et al.
Publicado: (2010)

Employing multiplex immunofluorescence to quantify Her2 and phosphorylated Her2 in formalin-fixed, paraffin-embedded breast tumor specimens
por: Donovan, MJ, et al.
Publicado: (2009)

An audit of breast imaging scoring by radiologists, in cases of proven malignancy
por: Powell, JR, et al.
Publicado: (2011)

The amalgamation of two breast imaging units in Leeds
por: Fletcher, ME, et al.
Publicado: (2004)

Breast pain in the over 40s: impact on imaging
por: Kulkarni, Trupti, et al.
Publicado: (2015)

Imaging methods in differentiation between inflammatory breast cancer and post-treatment changes
por: Lehotska, V, et al.
Publicado: (2006)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
por: Hinner, Marlon J, et al.
Publicado: (2015)

A retrospective review of triple-negative breast cancer cases: are there common features in the clinical presentation, imaging and risk factors?
por: Trevett, N, et al.
Publicado: (2010)

Evaluation of the anti-angiogenic action of melatonin in breast cancer
por: Jardim, Bruna V, et al.
Publicado: (2013)

Efficacy and safety of anti-TNF agents in patients with enthesitis related arthritis
por: Tynjälä, P, et al.
Publicado: (2008)

Clinical value of hybrid imaging for staging breast cancer in a district general hospital
por: Canavan, FR, et al.
Publicado: (2010)

An audit of preoperative magnetic resonance imaging staging of the breast
por: Bagnall, M, et al.
Publicado: (2006)

PB.26: Significance of flat epithelial atypia at image guided breast biopsy
por: Dani, S, et al.
Publicado: (2013)

Prognostic value HER-2/neu expression in T1 to T3 breast cancer with axillary lymph node metastasis
por: Maksimovic, S
Publicado: (2009)

Genetic engineering of pharmacologically regulated T cells, specific for breast cancer target antigens
por: Wilkie, S, et al.
Publicado: (2010)

Carbon nanomaterials as contrast agents for breast cancer diagnosis and therapy
por: Dolci, Sara, et al.
Publicado: (2015)

DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine
por: Anastasopoulou, Eleftheria A, et al.
Publicado: (2015)

Profiling of suppressive immune subsets in metastasis negative and positive sentinel lymph nodes from patients with HER2- breast cancer
por: van de Ven, Rieneke, et al.
Publicado: (2014)

An imaging review of extramedullary myeloma
por: Kay, M, et al.
Publicado: (2015)

Flow imaging in vivo using off resonance spin labeling induced by extraneous contrast agent
por: Bastiaansen, Jessica A, et al.
Publicado: (2016)

HER2 assessment using fluorescence in situ hybridization compared with Oncotype DX and association with risk of breast cancer death
por: Baehner, FL, et al.
Publicado: (2009)

Role of molecular functional imaging in present era of evidence based cancer medicine: to image or to imagine?
por: Mahajan, A, et al.
Publicado: (2015)

The role of magnetic resonance imaging (MRI) in invasive lobular breast cancer based on mammographic density
por: Bansal, GJ, et al.
Publicado: (2015)

Assessment of the dynamic range in dynamic contrast-enhanced magnetic resonance imaging breast examinations
por: Ledger, AEW, et al.
Publicado: (2012)

Breast screening with magnetic resonance imaging in high-risk women
por: McLean, L, et al.
Publicado: (2012)

Are there features on imaging or core biopsy that can predict tumour-positive margins after breast-conserving surgery?
por: Hill, N, et al.
Publicado: (2010)

PB.36. Imaging in gynaecomastia: audit of referral and imaging practise to establish referral guidelines
por: Bonam, K, et al.
Publicado: (2014)

Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?
por: Murphy, ML, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_1b0s0n18u9h04bt72dt30ctb88